Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Status:
Recruiting
Trial end date:
2030-05-31
Target enrollment:
Participant gender:
Summary
This phase I/II pilot study aims to enhance the effectiveness of stem cell transplant for
children and young adults with high-risk acute myeloid leukemia (AML). Patients will undergo
a stem cell transplant from a half-matched family donor. One week later, patients will
receive an additional infusion of immune cells and a drug called interleukin-2.
To mitigate the potential complications associated with graft-versus-host-disease, the
donated stem cell product undergoes a process that removes a specific type of immune cell.
After transplant, recipients are administered additional immune cells known as memory-like
natural killer (ML NK) cells. These cells are derived by converting conventional natural
killer cells obtained from the donor.
The infusion of a modified stem cell product, along with administration of ML NK cells may
help prevent the development of GvHD while simultaneously improving the efficacy of the
treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Rising Tide Foundation St. Louis Children's Hospital Foundation The Leukemia and Lymphoma Society